Comparing Olanzapine and Mirtazapine in the Improvement of Unintentional Weight Loss for Patients With Advanced Stage Cancer
Anorexia Nervosa With Significantly Low Body Weight
About this trial
This is an interventional treatment trial for Anorexia Nervosa With Significantly Low Body Weight
Eligibility Criteria
Inclusion Criteria:
• 18 years of age or older
- Able to provide informed consent
- Pathologically and/or clinically confirmed diagnosis of advanced cancer
At any point of treatment with standard chemotherapy*
o Scheduled to start, have discontinued or completed, or currently receiving
Greater than or equal to 5% unintentional weight loss over the previous 3-6 months, not explained by simple starvation
o Simple starvation is considered to be excluded when weight loss is not ameliorated by standard nutritional counseling and oral supplementation over a 2-week period).
- Life expectancy of at least 4 months
Able to communicate well and comply with study requirements, including by phone and written logs
- Patients on Dexamethasone will be allowed
Exclusion Criteria:
• Abnormal liver function defined as > twice upper limit of normal
Elevated QTc
o EKG performed within 1 year of enrollment will be accepted
- Total parental nutrition (TPN) or enteral feeds (PEG/PEJ) for >70% of their primary source of daily calorie intake
- Taking Marinol within 2 week of enrollment onto study
Sites / Locations
- Englewood Health
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Olanzapine
Mirtazapine